Galen Clinic
- Address
- lock Available on a paid plan
Immune System Diseases
Galen Clinic advances treatment for autoimmune neuromuscular disorders, concentrating on conditions such as generalized Myasthenia Gravis and chronic inflammatory demyelinating polyneuropathy, by testing innovative antibody‑based therapies and novel delivery methods.
- Evaluation of new antibody therapies for seronegative Myasthenia Gravis
- Subcutaneous formulation of efgartigimod for CIDP patients
- Long‑term safety and efficacy of batoclimab in active CIDP
- Assessment of zilucoplan in maintaining clinical response in generalized Myasthenia Gravis
- Comparative dosing regimens of efgartigimod IV in Myasthenia Gravis
With 20 active studies, the site aims to broaden therapeutic options and improve patient outcomes for immune‑mediated diseases, while ensuring safety and tolerability of emerging treatments.
Nervous System Diseases
Research at Galen Clinic targets neurodegenerative and demyelinating disorders, including Alzheimer disease, multiple sclerosis, and trigeminal neuralgia, focusing on disease‑modifying agents, cognitive enhancement, and pain relief.
- Disease‑modifying therapy assessment for relapsing multiple sclerosis
- Cognitive benefit of GV1001 in mild‑to‑moderate Alzheimer disease
- Pain reduction in trigeminal neuralgia using basimglurant
- Management of agitation in Alzheimer’s dementia with AVP‑786
- Early intervention study of donanemab in symptomatic Alzheimer disease
The trials strive to slow disease progression, enhance cognition, and alleviate symptoms, offering patients access to cutting‑edge therapies within a supportive clinical environment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 30 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Galen Clinic
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Empasiprubart in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Argenx | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 30 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Efgartigimod Alfa | 3 | Unknown | 2020-08-18 | 2024-10-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.